April 30, 2004 — An infusion of n-3 polyunsaturated fatty acids (PUFA) had immediate inhibitory effects on sustained ventricular tachycardia, according to the results of a pilot study published in the ...
Please provide your email address to receive an email when new articles are posted on . Patients with scar-related ventricular tachycardia (VT) who received VT ablation plus a subcutaneous ICD had ...
Good morning, and welcome to Lexeo Therapeutics webcast presentation on LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy. As a reminder, this call is being recorded today, ...
CHICAGO -- For patients with ventricular tachycardia (VT) and ischemic cardiomyopathy, going right to catheter ablation improved outcomes compared with trying antiarrhythmic drugs first, the VANISH2 ...
Agency’s Breakthrough Device Designation Program Allows for Priority Review of Ablation Technology for Ventricular Tachycardia The FDA Breakthrough Device Program, which reflects the FDA’s commitment ...
A new technology using ultralow temperature cryoablation (ULTC) has eliminated clinical ventricular tachycardia (VT) in 94% of patients. The late-breaking science is presented at EHRA 2024, a ...
Patients with ventricular tachycardia and ischemic cardiomyopathy are at high risk for adverse outcomes. Catheter ablation is commonly used when antiarrhythmic drugs do not suppress ventricular ...
Ventricular tachycardia, or V-tach (VT), and supraventricular tachycardia (SVT) are two types of tachycardia. The term “tachycardia” refers to a heart rate of more than 100 beats per minute. The key ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results